Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases.

Johann Wolfgang Goethe-Universität Frankfurt am Main0 个研究点目标入组 0 人开始时间: 2006年4月21日最近更新: 2017年10月2日

试验速览

暂无简介。

•Patients age between 0 and 30 years
•Written informed consent from the patient or from at least one of the patient’s parents (person having the care and custody of the child)
•Patients with a Karnofsky Index > 60%
•A malignant disease:
•acute lymphatic leucemia
•acute myeloic leucemia
•myelodysplastic syndrome
•chronic myeloic leucemia according to the standard indications
•Solid Tumors (e.g. relapse of a neuroblastom, soft tissue sarcoma, Ewing sarcoma, osteo sarcoma, hepatoblastome
•Or a non-malignant disease:
•Acquired anemia (e.g. severe aplastic anemia, in particular the severe form of the Evans syndrome)
•congenital anemia (e.g. thalassemia; sickle cell anemia)
•A reliable contraception has to be observed in sexual reproductive women
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patient or responsible person (person having the care and custody of the child), who is not able to understand the character and implications of this clinical trial
•Pregant or breast-feeding women
•Patients with a prior history of a stem cell transplantation within the last 250 days
•Renal, cardiac or hepatic insufficiency

发起方